Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4G7U)

• Drug Name: 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea Drug Info
• Synonyms: 1-(2-Hydroxy-4-nitrophenyl)-3-phenylurea; 80883-76-7; CHEMBL280711; NSC157449; AC1MUHEY; 1-(2-Hydroxy-4-nitro-phenyl)-3-phenyl-urea; SKampF 83589; GTPL834; SCHEMBL5595180; CTK9A5291; DTXSID00394355; ZINC3936851; BDBM50140794; AKOS024384917; NSC-157449; MCULE-1458670709; NSC 157449; N-(2-hydroxy-4-nitrophenyl)-N'-phenylurea; ST51035446; [(2-hydroxy-4-nitrophenyl)amino]-N-benzamide; N-(2-hydroxy-4-nitrophenyl)-N'-(phenyl); 1-(2-Hydroxy-4-nitro-phenyl)-3-phenyl-urea; SK&F 83589

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3618472
  CAS Number: CAS 80883-76-7
  TTD Drug ID: DMN4G7U

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 1 (CXCR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[4]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[4]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[5]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[6]
INDOPROFEN	DM5QSKN	Gout	FA25	Withdrawn from market	[4]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[4]
2-(3-Isopropyl-phenyl)-propionic acid	DMUOWNE	Discovery agent	N.A.	Investigative	[4]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	DMWIUR0	Discovery agent	N.A.	Investigative	[4]
(R)-2-(4-Isobutyl-phenyl)-propionamide	DMBQ0PR	Discovery agent	N.A.	Investigative	[4]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	DMWRIQG	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[4]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[7]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[4]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[9]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[10]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[13]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[2]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 834).
• [2] Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21.
• [3] Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem. 1998 Apr 24;273(17):10095-8.
• [4] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
• [7] Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
• [8] CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
• [9] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [10] Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
• [11] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [14] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.